Nicholas Sanderson was working the checkout line at a Woolworths supermarket when the idea first crystallized. Allied health practitioners—physiotherapists, speech pathologists, occupational therapists—were drowning in paperwork, their days consumed by billing codes and progress notes instead of actual patient care. Seven years later, his Adelaide-based company Splose announced a $46 million Series A round on February 9, the kind of capital infusion South Australia rarely sees.
The lead investor? Spectrum Equity, a Boston-based growth firm whose $2 billion Fund X has backed the likes of GoodRx and SurveyMonkey. Athletic Ventures, the Australian athlete-backed fund that's become a fixture in local tech deals, came along as co-investor. Splose is calling it the largest growth capital raise ever closed by a South Australian software company—a claim that, if accurate, says as much about the state's startup ecosystem as it does about this particular deal.
Now comes the hard part.
The Playbook: AI Meets Allied Health
Splose isn't reinventing practice management software. The core is table stakes: scheduling, online bookings, invoicing, telehealth, progress notes. What the company is betting on is that AI can tip the competitive scales in a crowded market that already includes Cliniko, Power Diary, and CorePlus across Australia and New Zealand.
The platform's AI layer, built on OpenAI's infrastructure, handles voice-to-text note capture. It generates clinical summaries and patient letters, analyzes documents, and—in a forthcoming release the company is calling "AI Blocks"—will pull detailed notes directly from transcripts and patient histories. Whether these features prove to be must-haves or nice-to-haves remains an open question. AI tooling is rapidly becoming commodity; maintaining a durable edge will require more than being first to market with GPT-powered transcription.
The software integrates with systems allied health practitioners actually use: Xero for accounting, Tyro Health for Medicare claims, HICAPS for NDIS billing, Stripe for payments. Pricing sits at A$27 per practitioner monthly. Non-practitioner roles—administrative staff, for instance—are free, a model that smooths adoption in multi-person clinics.
Splose launched its AI capabilities in July 2024. By January 2026, the company said on LinkedIn it had grown headcount 2.4x and now supports roughly 23,000 clinicians, up from the 20,000 figure cited in the funding announcement. (Minor discrepancies like this are common in fast-growing startups where metrics update faster than press releases.)
Following the Money
This isn't Splose's first rodeo. The company raised A$1 million in seed funding back in August 2022, then A$5 million in February 2025 led by EVP, the Melbourne-based early-stage firm. At the time of that earlier round, EVP pointed to metrics that caught investor attention: a 75% trial-to-paid conversion rate, annual recurring revenue around $6 million, and year-over-year growth of 115%.
Those numbers apparently impressed Spectrum Equity enough to write a check roughly nine times the size of the prior round. For context, Spectrum typically plays further up the growth curve—companies with proven product-market fit looking to scale internationally or consolidate categories. Their portfolio skews toward software businesses with strong unit economics and clear paths to dominance in defined niches.
That Spectrum sees Splose as fitting that profile tells you something about where allied health practice management may be headed. Perhaps more than the founders initially expected.
The NDIS Factor
Australia's National Disability Insurance Scheme is impossible to ignore when you're building software for allied health professionals. With approximately 717,000 participants and annual costs pushing $50 billion, the scheme represents both opportunity and complexity. NDIS compliance isn't optional; it's foundational. Splose has made claims integration and scheme navigation core to the product, a savvy read of the local market.
But the UK is a different story. Splose entered that market in July 2024, the same month it rolled out AI features—timing that suggests the company views its tech layer as a wedge into competitive foreign markets. The UK's NHS ecosystem is Byzantine in its own right, and the allied health landscape there includes entrenched players with existing relationships and local knowledge.
Sanderson, who studied commerce at the University of Adelaide and built Splose out of Adelaide's Stone & Chalk innovation hub, is betting $46 million that the platform can travel. Current headcount sits somewhere between 51 and 200 employees, according to available data—a range that's frustratingly imprecise but reflective of how fast the team is moving.
Momentum Versus Market Share
Splose has collected some of the credibility markers that startups covet. G2 named it a "#1 Momentum Leader" in practice management software this past January. The Australian Financial Review put the company on its Most Innovative list. These accolades matter for recruitment and sales cycles, though they're lagging indicators of actual market position.
The real test will be execution over the next 18 to 24 months. Can Splose establish a foothold in the UK while defending and expanding its Australian base? Can it maintain product velocity as larger, better-capitalized competitors roll out their own AI features—as they inevitably will? And perhaps most critically, can it prove that allied health practitioners will pay for software sophisticated enough to justify a $46 million valuation?
The company's growth trajectory suggests it's onto something. Whether "something" becomes "category leader across multiple English-speaking markets" or "solid regional player with decent exits for early backers" depends on variables well beyond AI transcription quality. Distribution, customer success, pricing power, competitive moats—the unglamorous mechanics of SaaS scaling will determine the outcome.
For now, Splose has the capital, the momentum, and the founder story that plays well in press releases. What it needs next is the kind of relentless execution that turns regional success stories into genuine market makers.
And that, for better or worse, can't be automated away with OpenAI credits.
